Approval · Notice of Compliance 20237 · 2018
ACT DUTASTERIDE: Notice of Compliance 20237
Issued January 3, 2018
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 20237
- Date
- January 3, 2018
- Company
- Teva Canada LimitedToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- Merger - buyout
- Canadian reference product
- AVODART (Glaxosmithkline Inc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ACT DUTASTERIDE | 02412691 | Cancelled Post Market |
Medicinal ingredients
- DUTASTERIDE 0.5 MG per CAP